GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

An activist investor is reportedly building a significant position in the drugmaker.

Why GlaxoSmithKline Stock Jumped Today

GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the candidate could potentially address a multimillion-dollar market, according to BofA Securities.

BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing

Shares of GlaxoSmithKline rose 6% on Thursday after reports of hedge fund Elliott Management taking a multi-billion pound stake at the British pharmaceutical firm. GSK rose to a high of $38.24, its highest price since January 28. It was last at $38.04 around 10:22 a.m. ET, up around 5.3%.

GSK climbs 6% on report of Elliot Management's multibillion stake (GSK)

GlaxoSmithKline gained Thursday on a report activist investor Elliott Management has built a "significant" stake in the pharmaceutical giant. In early action, GSK stock gapped up.

GlaxoSmithKline Surges On Report Activist Investor Takes 'Significant' Stake

GlaxoSmithKline PLC (LON:GSK) is on the radar of hedge fund group Elliott Management Advisers, according to a report today. The activist fund manager has acquired what was described as a significant stake, according to the Financial Times, at a time when concerns about its performance and that of chief executive Emma Walmsley have been growing said the newspaper.

GlaxoSmithKline shares rally on report activist Elliot has stake

Shares of U.K. pharmaceutical GlaxoSmithKline surged on Thursday, after a report said that activist investor Elliott Management has built a stake.

London Markets: GlaxoSmithKline shares surge on report Elliott Management building a stake

A top leader of GlaxoSmithKline's vaccine business is leaving the pharmaceutical giant. Emmanuel Hanon, GSK's head of vaccine research and development, is set to join Viome, a small microbiome-focused biotech company. He'll be Viome's global head of research and development and is set to start on July 1.

EXCLUSIVE: GlaxoSmithKline's vaccine R&D chief is departing for microbiome upstart Viome

Activist hedge fund Elliott Management has taken a multi-billion pound stake in British pharmaceutical firm GlaxoSmithKline, the Financial Times reported on Thursday.

Elliott takes multibillion pound stake in GSK, FT says

The small biotech is getting critical help from a big pharma company.

How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?

Eli Lilly

Vir Biotechnology

One of the three clearly has the most upside potential.

Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

Big 5 Sporting Goods

CTO Realty Growth

Equity Commonwealth

Intuit

JD.com

Lincoln Educational Services

Cheap, solid stocks may seem like a mirage considering the equity bull run, but several excellent investments are trading at a discount. The post 7 Cheap Stocks That Won't Be on Discount for Long appeared first on InvestorPlace.

7 Cheap Stocks That Won't Be on Discount for Long

AbbVie

Gilead Sciences

Pfizer

Healthcare is one of the most defensive sectors and often contains strong moats. Fortunately for income investors, there are also numerous high-yield opportunities in the space.

4 High-Yield Healthcare Stocks That Could Richly Reward Investors

Sanofi

There are five billion reasons these companies hope it's not.

Is the Market For a Flu Vaccine Disappearing?

Royalty Pharma

Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, Royalty Pharma has purchased royalties on cabozantinib products' net sales in non-U.S. markets through the entire duration of the royalty and royalties on net sales in the U.S. through September 2026 after which U.S. royalties will remain with GSK.

Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK

Novavax

GlaxoSmithKline PLC (LON:GSK) announced it will help making up to 60mln doses of the COVID-19 vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm signed an agreement in principle with Novavax and the UK Government.

GlaxoSmithKline to help making 60mln Novavax COVID-19 vaccine doses in UK plant

GlaxoSmithKline Plc (NYSE: GSK) has agreed to handle the final part of the manufacturing process for up to 60 million doses of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine for use in the U.K. GSK will provide ‘fill and finish' manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May.

Glaxo To Fill About 60M Novavax COVID-19 Shots For Britain

BHP Billiton

Ecopetrol

Fanhua

AT&T

W. P. Carey

Exxon Mobil

These 7 high-yield dividend stocks have yields above 5% and their payout ratios broadly look strong enough to support those dividends. The post 7 High-Yield Dividend Stocks With Enough Earnings to Cover the Dividends appeared first on InvestorPlace.

7 High-Yield Dividend Stocks With Enough Earnings to Cover the Dividends

Eli Lilly & Co. , Vir Biotechnology Inc. and GlaxoSmithKline PLC on Monday reported positive data from a Phase 2 trial evaluating the combination of two monoclonal antibodies in treating low-risk adult COVID-19 patients. The trial found combining Lilly's bamlanivimab with Vir's VIR-7831 showed a 70% reduction in persistently high viral load at day 7 compared to placebo.

Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition. What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses.

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

GlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for mild-to-moderate COVID-19 in adults and adolescents aged 12 and older who are at risk of hospitalization or death. The companies said early data from a Phase 3 trial found the treatment showed an 85% reduction in hospitalization or death compared to placebo.

GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatment

GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

GlaxoSmithKline fired Dr. Moncef Slaoui from the board for Galvani Bioelectronics on Wednesday on allegations he sexually harassed a GSK employee. In response, GlaxoSmithKline stock dipped.

Former OWS Chief Boosted From GSK Outfit On Sexual Harassment Claims

GlaxoSmithKline PLC (LON:GSK) announced it has fired Moncef Slaoui as chair of Galvani Bioelectronics, a chronic disease research firm where it is the majority shareholder. Slaoui is the former head of the FTSE 100 firm's vaccines department and lead the US government's Operation Warp Speed, a project announced by Donald Trump to develop a COVID-19 jab, from May 2020 to January 2021.

GlaxoSmithKline dismisses former US vaccine executive from board of investee over sexual harassment allegations

Moncef Slaoui, former chief scientist of Operation Warp Speed during the Trump administration, was fired as Galvani Bioelectronics' board chairman over “substantiated” sexual harassment allegations by a woman. Galvani Bioelectronics is a medical research company focused on developing bioelectronic medicines for the treatment of chronic diseases.

GSK Fires Moncef Slaoui Over Sexual Harassment Charges

GlaxoSmithKline said it's terminated Moncef Slaoui, the former head of Operation Warp Speed, as chair of majority held Galvani Bioelectronics. Glaxo said the termination came after a letter alleged sexual harassment and inappropriate conduct towards an employee when Slaoui was at Glaxo.

Glaxo says it's terminated former Trump vaccine czar over harassment allegation

News for GlaxoSmithKline Stock (GSK)